Translational Committee Asthma Prevention

The Translational Committee for the Asthma Prevention Consortium was formed with the aim of steering the scientific strategy and expediting the translation of scientific discovery into meaningful health outcomes. Their first face-to-face meeting was at the end of June in Munich, hosted by the principal researchers of the Asthma Prevention Consortium during its annual meeting.

The committee members represent relevant fields of expertise and experience, among which healthcare, life sciences, entrepreneurship, and the patients’ view. The committee advises Lung Foundation Netherlands on the opportunities and possibilities for translation.

Members of the committee

• Jeffrey Drazen, MD
  Editor-in-Chief of the New England Journal of Medicine
  Distinguished Parker B. Francis Professor of Medicine, Harvard Medical School
• Paul Peter Tak, PhD, MD
  CEO Kintai Therapeutics
  Professor of Medicine, University of Amsterdam
• Anne Leendertse, PhD
  Clinical Pharmacist 
  Patient Representative
• René Raggers, PhD
  Senior European and Dutch Patent Attorney
• Hans Bisgaard, MD, DMSc
  Professor of Pediatrics
  Copenhagen Prospective Studies on Asthma in Childhood (COPSAC)

During the Consortium meeting in Munich all those involved in the clinical trial on minimally processed milk, from scientists to the research nurses responsible for the recruitment of the participants, gathered to exchange insights and progress. Over the next months, we will months, we will share with you their challenges and experiences.

The Patient Advisory Committee has five members (from the UK and the Netherlands), representing the patients’ perspective within the consortium.